Vor Biopharma Inc. (VOR)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – What’s Next?

Telitacicept Demonstrates Deep and Durable Minimal Symptom  Expression Through 48 Weeks in Generalized Myasthenia Gravis

Vor Biopharma: A Funded Replication Story With Franchise Potential

Vor Biopharma Inc. (VOR) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial and Expands Telitacicept Global Franchise into Ocular Myasthenia Gravis

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bank of America Corp DE Has $2.01 Million Stock Holdings in Vor Biopharma Inc. $VOR

Vor Bio To Participate in Upcoming September Conferences

Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)